Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Bob Rudd who wrote (77314)	3/26/2025 8:17:56 PM
From: Madharry	Read Replies (2) \| Respond to of 78783

interesting find looks like a leveraged Merck spinoff. how sustainable is the dividend.? will tariffs be an issue?

To: Bob Rudd who wrote (77314)	5/1/2025 9:24:34 AM
From: E_K_S	Read Replies (2) \| Respond to of 78783

Re: Organon & Co. (OGN) Shares of Organon ( OGN, Financial) plunged approximately 13% in premarket trading after the company announced a significant cut in its quarterly dividend to $0.02 per share from $0.28. This decision comes as the Merck spinoff, focused on women's health and biosimilars, aims to revise its capital allocation goals to reduce debt. Organon plans to achieve a net leverage ratio below 4.0x by the end of the year. This announcement coincided with its Q1 2025 results, which exceeded earnings expectations but met revenue forecasts, reporting $1.7 billion in revenue.